Constitution of Cerebrospinal Fluid and Blood Database/Specimen in Acute Stage of Subarachnoid Hemorrhage (aSAH) Patients

Sponsor
University of Regensburg (Other)
Overall Status
Unknown status
CT.gov ID
NCT01292278
Collaborator
Technische Universität München (Other)
90
1
131
0.7

Study Details

Study Description

Brief Summary

Neuropeptide Y (NPY) may play a major role in the pathophysiology of aneurysmal subarachnoid hemorrhage (aSAH). To investigate the correlation of NPY in cerebrospinal fluid (CSF) and blood (serum) and the neurological outcome in the acute stage of aSAH.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Evaluation of Neuropeptides in CSF and serum in SAH patients

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    90 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Possible Role of Neuropeptide Y After Spontaneous Subarachnoid Hemorrhage
    Study Start Date :
    Jan 1, 2006
    Anticipated Primary Completion Date :
    Aug 1, 2015
    Anticipated Study Completion Date :
    Dec 1, 2016

    Arms and Interventions

    Arm Intervention/Treatment
    aSAH

    consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage

    control group

    no neurological disease but spinal anesthesia

    Outcome Measures

    Primary Outcome Measures

    1. Glasgow Outcome Scale [2011-2016]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • spontaneous or aneurysmal subarachnoid hemorrhage
    Exclusion Criteria:
    • age younger than 18 years or older than 70 years

    • inflammatory disease

    • history of former SAH

    • no ventricular drainage

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Neurosurgery Medical Center University of Regensburg Regensburg Germany 93053

    Sponsors and Collaborators

    • University of Regensburg
    • Technische Universität München

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Karl-Michael Schebesch, Karl-Michael Schebesch, MD, University of Regensburg
    ClinicalTrials.gov Identifier:
    NCT01292278
    Other Study ID Numbers:
    • CSF 06/179
    First Posted:
    Feb 9, 2011
    Last Update Posted:
    Dec 5, 2014
    Last Verified:
    Dec 1, 2014
    Keywords provided by Karl-Michael Schebesch, Karl-Michael Schebesch, MD, University of Regensburg
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 5, 2014